About Us
Company Overview
Executive Team
Board of Directors
Contact
Science & Pipeline
Pipeline
Publications
Patients
Partners
Business Development
Media
Press Release
Careers
Corporate Culture
Job Opportunities
Investors
中文
中文
About Us
Company Overview
Executive Team
Board of Directors
Scientific Advisory Board
Contact
Science & Pipeline
Pipeline
Publications
Patients
Partners
Business Development
Media
Press Release
Media Report
Careers
Corporate Culture
Job Opportunities
Investors
Differentiated Innovative Medicines
Pipeline
AN2025 (buparlisib)
AN0025 (palupiprant)
AN4005
AN8025
AN1025
AN9025
Publications
R&D Platform
22
2023-10
ESMO Poster
Utilizing H&E Images and Digital Pathology to Predict Response to Buparlisib in SCCHN
06
2022-12
SABCS Poster
A multicenter, single-arm, open-label Phase I study of AN1004 (Pelareorep) oncolytic virus plus paclitaxel in Chinese patients with Hormone receptor-positive and HER2-negative advanced/static breast cancer (REO 026-1)
16
2022-02
Frontiers in Immunology
Antagonistic Antibody Targeting TNFR2 Inhibits Regulatory T Cell Function to Promote Anti-Tumor Activity
14
2021-04
AACR Poster
AN3025: an immune-stimulatory anti-human TNFR2 antibody with strong anti-tumor activity
17
2020-06
Journal for ImmunoTherapy of Cancer
First-in- human phase I study of immunomodulatory E7046, an antagonist of PGE2-receptor E-type 4 (EP4), in patients with advanced cancers
27
2019-09
ESMO Poster
A Phase 1b Study of E7046 (AN0025) in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative Treatment of Rectal Cancer
18
2019-07
JSMO Poster
A novel CSF1R/c-kit dual antagonist eliminates tumor associated macrophage without elevating intratumoral MDSC level
15
2019-03
ICHNO Poster
Buparlisib(AN2025), a potential treatment option for anti PD 1 non responding tumors
28
2018-02
Clinical Cancer Research
Molecular Alterations and Buparlisib Efficacy in Patients with Squamous Cell Carcinoma of the Head and Neck: Biomarker Analysis from BERIL-1
13
2017-10
Breast Cancer Res Treat
A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with static breast cancer: final analysis of Canadian Cancer Trials Group IND.213.
25
2017-01
Lancet Oncol
Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or static squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial